Resources from the same session
SO-12: Updated safety, efficacy and PK results from an open-label, multicenter, phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)
Presenter: Jian Li, China (People's Republic)
Session: Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer
Resources:
Webcast
O-2: Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs
Presenter: Jonathan Strosberg, United States
Session: Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer
Resources:
Webcast
Cases on Management Strategy in NETs
Presenter: Massimo Falconi, Italy
Session: Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer
Resources:
Slides
Webcast
Advances & Challenges in Chemoradiotherapy and Treatment Optimization in Anal Cancer
Presenter: Karin Haustermans, Belgium
Session: Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer
Resources:
Slides
Webcast
How to Integrate Prognostic and Predictive Biomarkers and New agents in Anal Cancer-Tailored Treatment
Presenter: Cathy Eng, United States
Session: Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer
Resources:
Slides
Webcast
Q&A
Presenter: George Demetri, United States; Karin Haustermans, Belgium; Juan Manuel O'Connor, Argentina; Harpreet Wasan, United Kingdom; Cathy Eng, United States
Session: Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer
Resources:
Webcast